Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market. Learn more on RHHBY stock here.

Vandana Singh Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their ...

ROCHE HOLDING AG (ADR) (RHHBY) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received ... Poseida - equivalent to 66% of the California company's stock - which had been tendered by shareholders at a price ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Poseida Therapeutics (PSTX) will cease trading on Nasdaq after the merger and will become a wholly owned subsidiary of Roche (OTCQX:RHHBY). PSTX stock price traded marginally higher, up 0.42% to $ ...

Roche (RHHBY) said Monday that it has received 510(k) clearance from the U.S. Food and Drug Administration for its highly-sensitive ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.